Stox
30
Rossari Biotech Limited
NSE: ROSSARI · Unclassified
₹427.30+1.40%06 Nov 2026
Ask the data
Instant answers about Rossari Biotech Limited — computed from its filings, no language modelMarket cap₹2,367 cr
Current price₹427.30
High / Low₹650 / ₹379
P/E15.5
P/B1.68
Book value₹254.1
ROE10.9%
ROCE13.5%
Debt / equity0.26
Dividend yield0.12%
EPS (TTM)₹27.57
Face value₹2
Price & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY21 | FY22 | FY23 | FY24 | FY26 | |
|---|---|---|---|---|---|
| Revenue | 709 | 1,483 | 1,656 | 1,831 | 2,396 |
| EBITDA | 123 | 183 | 223 | 250 | 286 |
| Operating margin | 17.3% | 12.4% | 13.5% | 13.6% | 11.9% |
| Interest | 3 | 13 | 22 | 19 | 29 |
| Depreciation | 23 | 48 | 63 | 60 | 79 |
| Profit before tax | 106 | 135 | 143 | 177 | 201 |
| Tax | 27 | 39 | 37 | 47 | 53 |
| Net profit | 80 | 98 | 107 | 131 | 149 |
| EPS ₹ | 15.56 | 17.81 | 19.46 | 23.67 | 26.95 |
| Operating cash flow | — | 29 | 152 | 43 | 65 |
| Capex | — | 38 | 33 | 131 | 265 |
| Dividend paid | — | 3 | 3 | 3 | 3 |
| Total assets | — | — | 1,368 | 1,572 | 2,289 |
| Equity | — | — | 915 | 1,048 | 1,333 |
Quarterly performance
last 25 quarters · ₹ crore| JUN '20 | SEP '20 | DEC '20 | MAR '21 | JUN '21 | SEP '21 | DEC '21 | MAR '22 | JUN '22 | SEP '22 | DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 109 | 172 | 210 | 218 | 231 | 385 | 428 | 439 | 435 | 425 | 389 | 406 | 411 | 483 | 464 | 473 | 490 | 498 | 513 | 544 | 586 | 582 | 685 | 697 | 698 |
| Operating profit | 24 | 30 | 34 | 35 | 37 | 44 | 47 | 52 | 58 | 57 | 54 | 55 | 58 | 64 | 64 | 64 | 65 | 66 | 65 | 68 | 72 | 69 | 77 | 81 | 87 |
| Operating margin | 21.7% | 17.5% | 16.2% | 16.1% | 16.1% | 11.4% | 10.9% | 11.9% | 13.3% | 13.3% | 13.9% | 13.4% | 14.1% | 13.1% | 13.7% | 13.5% | 13.3% | 13.2% | 12.6% | 12.5% | 12.3% | 11.8% | 11.3% | 11.6% | 12.5% |
| Other income | 2 | 4 | 1 | 3 | 3 | 4 | 6 | 2 | 1 | 1 | 1 | 3 | 2 | 1 | 4 | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 19 | 3 | 1 |
| Interest | 1 | 1 | 0 | 1 | 1 | 2 | 3 | 5 | 5 | 8 | 5 | 4 | 6 | 5 | 4 | 3 | 4 | 4 | 5 | 6 | 6 | 8 | 9 | 11 | 9 |
| Depreciation | 4 | 6 | 6 | 7 | 6 | 10 | 18 | 17 | 15 | 16 | 16 | 16 | 14 | 15 | 15 | 16 | 15 | 15 | 18 | 18 | 18 | 20 | 24 | 26 | 30 |
| Profit before tax | 20 | 28 | 28 | 30 | 33 | 36 | 32 | 33 | 38 | 34 | 35 | 37 | 40 | 45 | 48 | 45 | 47 | 48 | 42 | 46 | 49 | 42 | 64 | 47 | 49 |
| Tax | 5 | 7 | 7 | 8 | 9 | 10 | 9 | 10 | 10 | 10 | 9 | 8 | 10 | 12 | 13 | 11 | 12 | 13 | 11 | 12 | 13 | 10 | 18 | 13 | 10 |
| Net profit | 15 | 21 | 22 | 22 | 25 | 26 | 23 | 24 | 29 | 24 | 26 | 29 | 29 | 33 | 34 | 34 | 35 | 35 | 32 | 34 | 37 | 33 | 46 | 35 | 39 |
| EPS ₹ | 3.19 | 4.07 | 4.16 | 4.32 | 4.52 | 4.77 | 4.09 | 4.37 | 5.21 | 4.34 | 4.66 | 5.25 | 5.30 | 5.97 | 6.23 | 6.18 | 6.32 | 6.39 | 5.73 | 6.07 | 6.66 | 5.92 | 8.30 | 6.34 | 7.02 |
| Revenue YoY | — | — | — | — | 111.1% | 124.0% | 104.0% | 101.1% | 88.1% | 10.6% | -9.1% | -7.4% | -5.5% | 13.6% | 19.1% | 16.3% | 19.2% | 3.1% | 10.6% | 11.0% | 17.6% | 13.4% | — | 28.2% | 19.0% |
| Profit YoY | — | — | — | — | 58.3% | 26.7% | 4.4% | 7.4% | 17.0% | -8.8% | 13.9% | 20.3% | 1.9% | 37.8% | 33.9% | 17.8% | 19.4% | 7.2% | -7.8% | -3.7% | 4.4% | 3.4% | — | 4.4% | 5.5% |
Returns & margins
trailing-twelve-month, per quarter| MAR '21 | JUN '21 | SEP '21 | DEC '21 | MAR '22 | JUN '22 | SEP '22 | DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | 11.5% | 11.9% | 11.7% | 11.8% | 11.9% | 12.8% | 12.5% | 13.0% | 12.4% | 12.2% | 11.2% | 11.3% | 10.9% |
| ROCE | — | — | — | — | — | — | 17.0% | 17.4% | 16.7% | 17.0% | 15.9% | 17.0% | 17.0% | 17.4% | 16.0% | 15.6% | 13.2% | 13.6% | 13.5% |
| Net margin | 11.3% | 10.7% | 9.1% | 7.6% | 6.6% | 6.0% | 5.7% | 6.1% | 6.5% | 6.6% | 6.9% | 7.1% | 7.1% | 7.1% | 7.2% | 6.9% | 6.2% | 5.9% | 5.7% |
| EBITDA margin | 17.3% | 16.4% | 14.4% | 12.9% | 12.1% | 11.9% | 12.3% | 13.1% | 13.5% | 13.7% | 13.6% | 13.6% | 13.6% | 13.4% | 13.4% | 13.1% | 11.9% | 11.7% | 11.8% |
| Debt / equity | — | — | — | — | — | — | 0.08 | 0.08 | 0.08 | 0.08 | 0.13 | 0.13 | 0.10 | 0.10 | 0.13 | 0.13 | 0.31 | 0.31 | 0.26 |
| Interest coverage | 36.60 | 49.10 | 35.22 | 20.08 | 13.32 | 10.06 | 7.31 | 7.11 | 7.42 | 7.14 | 8.66 | 9.45 | 10.75 | 12.87 | 14.21 | 13.27 | 8.03 | 6.98 | 6.55 |
| Asset turnover | — | — | — | — | — | — | 1.32 | 1.29 | 1.21 | 1.19 | 1.10 | 1.15 | 1.16 | 1.21 | 1.12 | 1.15 | 1.05 | 1.11 | 1.13 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '22 | MAR '23 | SEP '23 | MAR '24 | SEP '24 | SEP '25 | MAR '26 | SEP '26 | |
|---|---|---|---|---|---|---|---|---|
| Share capital | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
| Other equity / reserves | 848 | 904 | 967 | 1,037 | 1,107 | 1,240 | 1,322 | 1,397 |
| Total equity | 859 | 915 | 978 | 1,048 | 1,118 | 1,252 | 1,333 | 1,408 |
| Borrowings | 71 | 74 | 132 | 106 | 143 | 324 | 408 | 362 |
| Current liabilities | 338 | 347 | 469 | 425 | 451 | 645 | 790 | 803 |
| Non-current liabilities | 114 | 106 | 87 | 100 | 142 | 192 | 166 | 149 |
| Total assets | 1,312 | 1,368 | 1,534 | 1,572 | 1,711 | 2,088 | 2,289 | 2,359 |
| Property, plant & equipment | 332 | 314 | 302 | 315 | 316 | 369 | 561 | 511 |
| Capital work-in-progress | 1 | 13 | 24 | 47 | 98 | 247 | 173 | 156 |
| Investments | 42 | 51 | 49 | 63 | 79 | 47 | 62 | 58 |
| Inventories | 199 | 188 | 283 | 282 | 328 | 381 | 405 | 444 |
| Receivables | 351 | 354 | 414 | 425 | 435 | 540 | 557 | 554 |
| Cash & equivalents | 50 | 70 | 51 | 25 | 19 | 36 | 75 | 84 |
Cash flow
annual · ₹ crore · line = free cash flow| FY22 | FY23 | FY24 | FY26 | |
|---|---|---|---|---|
| Cash from operations | 29 | 152 | 43 | 65 |
| Cash from investing | -299 | -181 | -103 | -219 |
| Cash from financing | 292 | 61 | 16 | 186 |
| Capex | 38 | 33 | 131 | 265 |
| Free cash flow | -9 | 120 | -88 | -200 |
| Dividends paid | 3 | 3 | 3 | 3 |
Where the assets sit
Sep '26 · ₹ croreFixed assets (PPE)₹511 cr22%
CWIP₹156 cr7%
Investments₹58 cr2%
Inventories₹444 cr19%
Receivables₹554 cr23%
Cash & equivalents₹84 cr4%
Other assets₹552 cr23%
Peer comparison
largest in Unclassified · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Avantel Limited | 36,86,04,549 | 138.69 | — | 1059360.68 | 0.0% |
| Ducol Organics And Colours Limited | 19,55,275 | 120.00 | — | 20089.13 | 0.0% |
| Jio Platforms Limited | 12,57,181 | 1,406.40 | — | 3.57 | — |
| SBI Funds Management Limited | 1,01,750 | 499.55 | — | — | — |
| Tamilnadu Telecommunication Limited | 91,314 | 9.93 | — | — | — |
| Manipal Health Enterprises Limited | 76,294 | 646.70 | — | — | — |
| INDO-MIM Limited | 59,042 | 1,219.50 | — | — | — |
| AvenuesAI Limited | 45,138 | 129.25 | 153.6 | 9.51 | 6.2% |
| Dhoot Transmission Limited | 32,761 | 1,601.60 | — | 8.11 | — |
| 3M India Limited | 31,071 | 27,570.00 | 53.8 | 17.57 | 32.7% |
| Rossari Biotech Limited | 2,367 | 427.30 | 15.5 | 1.68 | 10.9% |
StoxGud checklist: Bearish setup · 3/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
1 month+1.0%
6 months-20.8%
1 year-33.8%
3Y CAGR-15.7%
5Y CAGR-21.0%
10Y CAGR—
50-day avg₹437.86
200-day avg₹486.18
RSI (14)37
FAQs
What is the share price of Rossari Biotech Limited?
Rossari Biotech Limited (ROSSARI) closed at ₹427.30 on NSE on 06 Nov 2026.
What is the market cap of Rossari Biotech Limited?
₹2,367 crore at the latest close.
What is the P/E ratio of Rossari Biotech Limited?
15.5, on trailing-twelve-month earnings from its filings.
How fast is Rossari Biotech Limited growing?
Rossari Biotech Limited: revenue has compounded at 17.3% a year over three years; net profit at 15.2% a year. Latest-quarter revenue is up 19.0% year on year, profit up 5.5%.
How profitable is Rossari Biotech Limited?
On a trailing-twelve-month basis return on equity is 10.9%, return on capital employed 13.5%, operating margin 11.8%, net margin 5.7%.
How much debt does Rossari Biotech Limited have?
Rossari Biotech Limited is lightly geared: debt to equity is 0.26 with borrowings of ₹362 cr against cash of ₹84 cr (balance sheet of 2026-09-30). Operating profit covers interest 6.5 times.
Financials parsed from Rossari Biotech Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from JUN '20, annual from FY21, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.
Rossari Biotech Limited · advanced chart